
ImmunityBio Shares ISPOR 2026 Survey on Bladder Preservation Preference in UK NMIBC Patients
ImmunityBio Survey Highlights Diverse Treatment Priorities Among Patients With BCG-Unresponsive NMIBC ImmunityBio has unveiled new patient survey findings that shed light on how individuals living with Bacillus Calmette–Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (NMIBC) make treatment decisions following BCG therapy…












